Charles River Laboratories International Company Profile (NYSE:CRL)

About Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International logoCharles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NYSE:CRL
  • CUSIP: 15986410
  • Web:
  • Market Cap: $5.48138 billion
  • Outstanding Shares: 47,593,000
Average Prices:
  • 50 Day Moving Avg: $109.43
  • 200 Day Moving Avg: $99.39
  • 52 Week Range: $67.20 - $115.96
  • Trailing P/E Ratio: 30.28
  • Foreward P/E Ratio: 20.41
  • P/E Growth: 2.08
Sales & Book Value:
  • Annual Revenue: $1.81 billion
  • Price / Sales: 3.02
  • Book Value: $20.25 per share
  • Price / Book: 5.67
  • EBITDA: $435.89 million
  • Net Margins: 10.13%
  • Return on Equity: 27.02%
  • Return on Assets: 8.84%
  • Debt-to-Equity Ratio: 1.16%
  • Current Ratio: 1.74%
  • Quick Ratio: 1.49%
  • Average Volume: 361,717 shs.
  • Beta: 0.96
  • Short Ratio: 5.44

Frequently Asked Questions for Charles River Laboratories International (NYSE:CRL)

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How will Charles River Laboratories International's stock buyback program work?

Charles River Laboratories International declared that its board has authorized a stock buyback plan on Sunday, June 4th 2017, which allows the company to buyback $150,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) announced its quarterly earnings data on Wednesday, August, 9th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company's revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.20 earnings per share. View Charles River Laboratories International's Earnings History.

When will Charles River Laboratories International make its next earnings announcement?

Charles River Laboratories International is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Charles River Laboratories International.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International issued an update on its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share guidance of $5.00-5.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.10. The company issued revenue guidance of $1.82-1.85 billion (+8.5-10%), compared to the consensus revenue estimate of $1.83 billion.

Where is Charles River Laboratories International's stock going? Where will Charles River Laboratories International's stock price be in 2017?

9 brokerages have issued twelve-month price targets for Charles River Laboratories International's shares. Their predictions range from $77.00 to $130.00. On average, they anticipate Charles River Laboratories International's share price to reach $103.17 in the next year. View Analyst Ratings for Charles River Laboratories International.

What are analysts saying about Charles River Laboratories International stock?

Here are some recent quotes from research analysts about Charles River Laboratories International stock:

  • 1. According to Zacks Investment Research, "Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years. " (8/11/2017)
  • 2. UBS AG analysts commented, "CRL reported 4Q16 results with reported revenue of $467m, above both our estimate of $442m and consensus estimates of $441m. Adj. EPS of $1.21 was above both ours and consensus estimates of $1.11. Management guided to 7.5% ' 9% revenue growth (7% ' 8.5% org.) and adj. EPS of $5.00 - $5.10 for FY17. For 1Q17, reported revenue growth is expected in the mid-20% and adj. EPS growth of mid- to high-teens' Our Sell rating is based on the following: 1) We are becoming more selective in our CRO universe and CRL is primarily exposed to early development markets which we think are most at risk should biopharma markets slow. 2) We estimate that street forecasts for 2017 are too high and think CRL's multiple could revert to its mean should estimates need to come down as we anticipate. 3) We estimate that CRL is most at risk in our universe should interest rates begin to rise." (2/15/2017)
  • 3. Jefferies Group LLC analysts commented, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments. Guidance bracketed consensus, lower than us (as expected). We point to margin expansion (with continued price) and capital deployment as upside sources. Strong Discovery and Early Development demand (see our research pointing to funding shifts to Early Dev) should support high single digit organic growth." (2/15/2017)

Who are some of Charles River Laboratories International's key competitors?

Who are Charles River Laboratories International's key executives?

Charles River Laboratories International's management team includes the folowing people:

  • James C. Foster, Chairman of the Board, President, Chief Executive Officer
  • David R. Smith, Chief Financial Officer, Corporate Executive Vice President
  • David P. Johst, Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel
  • William D. Barbo, Corporate Executive Vice President and Chief Commercial Officer
  • Davide A. Molho, Corporate Executive Vice President & President, Global Research Models & Services, Safety Assessment and Biologics
  • Michael Gunnar Knell, Corporate Senior Vice President, Chief Accounting Officer
  • George M. Milne Jr., Ph.D., Lead Independent Director
  • Martin Mackay Ph.D., Director
  • Robert J. Bertolini, Independent Director
  • Stephen D. Chubb, Independent Director

Who owns Charles River Laboratories International stock?

Charles River Laboratories International's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.95%), Personal Capital Advisors Corp (0.25%), APG Asset Management N.V. (0.21%), Nationwide Fund Advisors (0.17%), Mutual of America Capital Management LLC (0.08%) and Shell Asset Management Co. (0.08%). Company insiders that own Charles River Laboratories International stock include C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, John J Crowley, Nancy Gillett, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Thomas F Ackerman and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories International.

Who sold Charles River Laboratories International stock? Who is selling Charles River Laboratories International stock?

Charles River Laboratories International's stock was sold by a variety of institutional investors in the last quarter, including Personal Capital Advisors Corp, Fisher Asset Management LLC, State Treasurer State of Michigan and Nationwide Fund Advisors. Company insiders that have sold Charles River Laboratories International stock in the last year include C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George Massaro, James C Foster, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories International.

Who bought Charles River Laboratories International stock? Who is buying Charles River Laboratories International stock?

Charles River Laboratories International's stock was acquired by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Shell Asset Management Co., Meeder Asset Management Inc., Fox Run Management L.L.C., Moloney Securities Asset Management LLC, CAPROCK Group Inc. and Mutual of America Capital Management LLC. View Insider Buying and Selling for Charles River Laboratories International.

How do I buy Charles River Laboratories International stock?

Shares of Charles River Laboratories International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Charles River Laboratories International's stock price today?

One share of Charles River Laboratories International stock can currently be purchased for approximately $114.91.

MarketBeat Community Rating for Charles River Laboratories International (NYSE CRL)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  531
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Charles River Laboratories International (NYSE:CRL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $103.17 (10.22% downside)
Consensus Price Target History for Charles River Laboratories International (NYSE:CRL)
Price Target History for Charles River Laboratories International (NYSE:CRL)
Analysts' Ratings History for Charles River Laboratories International (NYSE:CRL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Credit Suisse GroupReiterated RatingNeutral$95.00 -> $112.00N/AView Rating Details
10/9/2017Jefferies Group LLCBoost Price TargetBuy$120.00 -> $130.00N/AView Rating Details
9/19/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$110.00MediumView Rating Details
9/1/2017Robert W. BairdReiterated RatingBuy$114.00LowView Rating Details
7/19/2017Barclays PLCReiterated RatingHold$102.00LowView Rating Details
6/28/2017Citigroup Inc.Reiterated RatingNeutral$91.00 -> $104.00LowView Rating Details
1/4/2017Evercore ISIUpgradeHold -> Buy$86.50N/AView Rating Details
12/16/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$75.00 -> $77.00N/AView Rating Details
11/18/2016Bank of America CorporationSet Price TargetBuy$93.00N/AView Rating Details
5/22/2016KeyCorpReiterated RatingHold$77.00N/AView Rating Details
4/26/2016GabelliInitiated CoverageBuy$96.00N/AView Rating Details
2/11/2016Deutsche Bank AGReiterated RatingHold$85.00 -> $82.00N/AView Rating Details
1/7/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 10/24/2015 forward)


Earnings History for Charles River Laboratories International (NYSE:CRL)
Earnings by Quarter for Charles River Laboratories International (NYSE:CRL)
Earnings History by Quarter for Charles River Laboratories International (NYSE CRL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017$1.22N/AView Earnings Details
8/9/2017Q2 2017$1.22$1.29$458.25 million$469.13 millionViewListenView Earnings Details
5/10/2017Q1 2017$1.14$1.29$437.04 million$445.80 millionViewN/AView Earnings Details
2/14/2017Q416$1.11$1.21$441.64 million$466.80 millionViewListenView Earnings Details
11/2/2016Q316$1.13$1.18$291.20 million$425.70 millionViewListenView Earnings Details
8/3/2016Q216$1.10$1.20$425.05 million$434.10 millionViewListenView Earnings Details
5/4/2016Q116$0.90$0.98$354.92 million$354.90 millionViewListenView Earnings Details
2/10/2016Q415$0.94$1.00$349.20 million$353.90 millionViewListenView Earnings Details
11/4/2015Q315$0.94$1.03$340.09 million$349.50 millionViewListenView Earnings Details
7/30/2015Q215$0.97$0.96$338.30 million$339.60 millionViewListenView Earnings Details
4/29/2015Q115$0.82$0.79$324.00 million$320.40 millionViewListenView Earnings Details
2/10/2015Q414$0.71$0.81$318.73 million$329.50 millionViewListenView Earnings Details
10/29/2014Q314$0.80$0.86$326.70 million$327.60 millionViewListenView Earnings Details
8/6/2014Q214$0.82$0.97$327.96 million$341.18 millionViewListenView Earnings Details
4/30/2014Q114$0.74$0.82$302.08 million$299.40 millionViewListenView Earnings Details
2/12/2014Q413$0.68$0.73$289.56 million$289.20 millionViewListenView Earnings Details
10/30/2013Q313$0.70$0.79$290.28 million$292.10 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.71$0.73$293.77 million$294.40 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.71$0.69$294.53 million$291.20 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.60$0.64$280.81 million$280.10 millionViewListenView Earnings Details
10/30/2012$0.62$0.65ViewN/AView Earnings Details
8/7/2012$0.66$0.75ViewN/AView Earnings Details
5/2/2012$0.65$0.70ViewN/AView Earnings Details
2/13/2012$0.56$0.69ViewN/AView Earnings Details
11/1/2011$0.58$0.57ViewN/AView Earnings Details
8/2/2011$0.60$0.70ViewN/AView Earnings Details
5/3/2011$0.55$0.61ViewN/AView Earnings Details
2/8/2011$0.50$0.60ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Charles River Laboratories International (NYSE:CRL)
2017 EPS Consensus Estimate: $4.89
2018 EPS Consensus Estimate: $5.77
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$1.07$1.16$1.13
Q2 20175$1.21$1.29$1.23
Q3 20175$1.21$1.25$1.23
Q4 20175$1.24$1.34$1.31
Q1 20182$1.29$1.32$1.31
Q2 20182$1.45$1.46$1.46
Q3 20181$1.45$1.45$1.45
Q4 20181$1.56$1.56$1.56
(Data provided by Zacks Investment Research)


Dividend History for Charles River Laboratories International (NYSE:CRL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Charles River Laboratories International (NYSE:CRL)
Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 97.22%
Insider Trades by Quarter for Charles River Laboratories International (NYSE:CRL)
Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)
Insider Trades by Quarter for Charles River Laboratories International (NYSE:CRL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Davide MolhoInsiderSell6,165$110.00$678,150.00View SEC Filing  
9/5/2017Davide MolhoInsiderSell5,982$107.55$643,364.10View SEC Filing  
8/17/2017William D BarboInsiderSell4,000$99.91$399,640.00View SEC Filing  
8/14/2017David Ross SmithInsiderSell2,552$67.10$171,239.20View SEC Filing  
7/17/2017George MassaroDirectorSell3,830$100.81$386,102.30View SEC Filing  
7/10/2017James C FosterChairmanSell9,516$98.92$941,322.72View SEC Filing  
6/22/2017Davide MolhoInsiderSell10,948$100.00$1,094,800.00View SEC Filing  
6/22/2017James C FosterChairmanSell43,154$100.00$4,315,400.00View SEC Filing  
6/8/2017David Ross SmithInsiderSell945$95.00$89,775.00View SEC Filing  
5/26/2017Davide MolhoInsiderSell10,976$92.84$1,019,011.84View SEC Filing  
5/12/2017George MassaroDirectorSell1,130$88.30$99,779.00View SEC Filing  
3/16/2017Davide MolhoInsiderSell11,717$90.00$1,054,530.00View SEC Filing  
3/10/2017David P JohstInsiderSell34,593$89.06$3,080,852.58View SEC Filing  
3/6/2017William D BarboInsiderSell1,900$87.90$167,010.00View SEC Filing  
3/3/2017David Ross SmithEVPSell3,890$88.12$342,786.80View SEC Filing  
3/1/2017Robert J BertoliniDirectorSell5,255$87.53$459,970.15View SEC Filing  
2/28/2017James C FosterChairmanSell4,910$87.09$427,611.90View SEC Filing  
2/22/2017James C FosterChairmanSell9,717$87.64$851,597.88View SEC Filing  
1/30/2017David P JohstInsiderSell13,950$78.00$1,088,100.00View SEC Filing  
12/2/2016Stephen D ChubbDirectorSell4,564$71.57$326,645.48View SEC Filing  
11/28/2016C Richard ReeseDirectorSell4,539$71.93$326,490.27View SEC Filing  
8/30/2016Davide MolhoInsiderSell7,877$84.10$662,455.70View SEC Filing  
8/5/2016James C FosterChairmanSell18,351$85.63$1,571,396.13View SEC Filing  
7/29/2016Richard F WallmanDirectorSell7,740$88.00$681,120.00View SEC Filing  
7/1/2016George MassaroDirectorSell3,740$83.09$310,756.60View SEC Filing  
5/24/2016John J CrowleyCAOSell1,913$85.00$162,605.00View SEC Filing  
5/13/2016Richard F WallmanDirectorSell1,970$82.32$162,170.40View SEC Filing  
5/10/2016Richard F WallmanDirectorSell11,990$84.00$1,007,160.00View SEC Filing  
5/9/2016George MassaroDirectorSell985$82.17$80,937.45View SEC Filing  
5/6/2016Richard F WallmanDirectorSell2,720$81.00$220,320.00View SEC Filing  
4/6/2016Davide MolhoVPSell30,667$80.00$2,453,360.00View SEC Filing  
3/2/2016Nancy GillettVPSell7,015$75.00$526,125.00View SEC Filing  
2/29/2016Nancy GillettVPSell3,646$73.50$267,981.00View SEC Filing  
2/25/2016David P JohstVPSell34,075$73.02$2,488,156.50View SEC Filing  
2/24/2016James C FosterCEOSell3,873$70.40$272,659.20View SEC Filing  
2/23/2016George M Milne JrDirectorSell10,440$73.02$762,328.80View SEC Filing  
2/22/2016James C FosterCEOSell9,831$73.12$718,842.72View SEC Filing  
2/12/2016C Richard ReeseDirectorSell4,228$71.48$302,217.44View SEC Filing  
2/12/2016Nancy GillettVPSell6,750$71.90$485,325.00View SEC Filing  
2/1/2016Stephen D ChubbDirectorSell2,000$74.76$149,520.00View SEC Filing  
12/17/2015George MassaroDirectorSell7,740$80.00$619,200.00View SEC Filing  
12/17/2015Thomas F. AckermaninsiderSell10,000$80.00$800,000.00View SEC Filing  
11/19/2015Thomas F. AckermaninsiderSell10,000$75.00$750,000.00View SEC Filing  
11/4/2015Thomas F. AckermaninsiderSell21,612$70.01$1,513,056.12View SEC Filing  
11/2/2015Stephen D ChubbDirectorSell2,000$66.57$133,140.00View SEC Filing  
8/17/2015Thomas F AckermanInsiderSell5,000$75.53$377,650.00View SEC Filing  
5/15/2015Thomas F AckermanCFOSell3,900$70.51$274,989.00View SEC Filing  
5/7/2015George MassaroDirectorSell1,360$70.21$95,485.60View SEC Filing  
3/3/2015Stephen D ChubbDirectorSell2,000$75.52$151,040.00View SEC Filing  
3/2/2015Deborah Turner KochevarDirectorSell2,600$76.59$199,134.00View SEC Filing  
3/2/2015James C FosterCEOSell2,036$76.93$156,629.48View SEC Filing  
3/2/2015Nancy GillettVPSell4,379$76.72$335,956.88View SEC Filing  
2/27/2015Nancy GillettVPSell2,772$76.95$213,305.40View SEC Filing  
2/25/2015James C FosterCEOSell4,621$75.96$351,011.16View SEC Filing  
2/25/2015Nancy GillettVPSell5,015$76.12$381,741.80View SEC Filing  
2/24/2015James C FosterCEOSell4,800$75.70$363,360.00View SEC Filing  
2/24/2015Jorg GellerVPSell12,061$76.17$918,686.37View SEC Filing  
2/23/2015James C FosterCEOSell8,423$76.56$644,864.88View SEC Filing  
2/23/2015Jorg GellerVPSell7,041$76.59$539,270.19View SEC Filing  
2/20/2015George M Milne JrDirectorSell6,000$75.87$455,220.00View SEC Filing  
2/19/2015James C FosterCEOSell9,671$75.00$725,325.00View SEC Filing  
2/18/2015Stephen D ChubbDirectorSell5,011$73.97$370,663.67View SEC Filing  
2/17/2015Jorg GellerVPSell14,430$73.54$1,061,182.20View SEC Filing  
2/17/2015Thomas F AckermanCFOSell4,400$73.50$323,400.00View SEC Filing  
2/13/2015Davide MolhoVPSell19,075$74.00$1,411,550.00View SEC Filing  
2/12/2015Jorg GellerVPSell8,458$73.68$623,185.44View SEC Filing  
1/26/2015Thomas F AckermanCFOSell10,000$70.00$700,000.00View SEC Filing  
1/8/2015David P JohstVPSell4,737$67.00$317,379.00View SEC Filing  
1/7/2015David P JohstVPSell26,100$65.00$1,696,500.00View SEC Filing  
12/1/2014Stephen D ChubbDirectorSell2,000$64.44$128,880.00View SEC Filing  
11/28/2014David P JohstVPSell6,982$65.34$456,203.88View SEC Filing  
11/17/2014Thomas F AckermanCFOSell10,000$63.70$637,000.00View SEC Filing  
11/14/2014Jorg GellerVPSell5,610$63.57$356,627.70View SEC Filing  
11/6/2014C Richard ReeseDirectorSell5,849$63.39$370,768.11View SEC Filing  
11/4/2014John J CrowleyCAOSell1,000$64.00$64,000.00View SEC Filing  
11/3/2014Davide MolhoVPSell16,402$64.54$1,058,585.08View SEC Filing  
11/3/2014George MassaroDirectorSell16,710$65.00$1,086,150.00View SEC Filing  
11/3/2014Thomas F AckermanCFOSell36,100$65.00$2,346,500.00View SEC Filing  
10/30/2014Nancy GillettVPSell1,069$65.00$69,485.00View SEC Filing  
10/28/2014David P JohstVPSell74,780$64.00$4,785,920.00View SEC Filing  
10/3/2014James C FosterCEOSell136,647$62.00$8,472,114.00View SEC Filing  
9/29/2014Thomas F AckermanCFOSell5,000$60.00$300,000.00View SEC Filing  
9/4/2014Davide MolhoVPSell4,900$61.34$300,566.00View SEC Filing  
9/2/2014Stephen D ChubbDirectorSell2,000$59.18$118,360.00View SEC Filing  
8/26/2014George MassaroDirectorSell10,440$60.00$626,400.00View SEC Filing  
8/18/2014Thomas F AckermanCFOSell23,156$59.25$1,371,993.00View SEC Filing  
8/12/2014Richard F WallmanDirectorSell3,240$58.20$188,568.00View SEC Filing  
6/2/2014Stephen D ChubbDirectorSell2,000$52.93$105,860.00View SEC Filing  
5/22/2014Deborah Turner KochevarDirectorSell3,100$53.30$165,230.00View SEC Filing  
5/8/2014George MassaroDirectorSell1,620$52.70$85,374.00View SEC Filing  
5/5/2014Thomas AckermanCFOSell5,430$50.76$275,626.80View SEC Filing  
3/7/2014Nancy GillettVPSell10,110$58.36$590,019.60View SEC Filing  
3/4/2014Nancy GillettVPSell13,650$58.98$805,077.00View SEC Filing  
3/3/2014Stephen ChubbDirectorSell2,000$58.70$117,400.00View SEC Filing  
2/28/2014Jorg GellerVPSell7,486$59.41$444,743.26View SEC Filing  
2/27/2014Nancy GillettVPSell4,000$60.00$240,000.00View SEC Filing  
2/25/2014Jorg GellerVPSell3,188$58.49$186,466.12View SEC Filing  
2/20/2014Nancy GillettVPSell4,000$58.96$235,840.00View SEC Filing  
2/19/2014Stephen ChubbDirectorSell5,198$58.35$303,303.30View SEC Filing  
2/18/2014Thomas AckermanCFOSell14,000$58.05$812,700.00View SEC Filing  
1/13/2014David JohstVPSell19,750$58.00$1,145,500.00View SEC Filing  
1/7/2014George MassaroDirectorSell5,750$54.00$310,500.00View SEC Filing  
12/20/2013Thomas AckermanCFOSell5,000$52.72$263,600.00View SEC Filing  
12/4/2013Jorg GellerVPSell7,200$51.93$373,896.00View SEC Filing  
12/2/2013Stephen ChubbDirectorSell2,000$51.92$103,840.00View SEC Filing  
9/16/2013George MassaroDirectorSell5,958$47.38$282,290.04View SEC Filing  
9/9/2013James C FosterCEOSell174,479$47.00$8,200,513.00View SEC Filing  
9/4/2013Thomas F AckermanCFOSell6,100$46.13$281,393.00View SEC Filing  
9/3/2013Stephen ChubbDirectorSell2,000$46.49$92,980.00View SEC Filing  
8/29/2013James FosterCEOSell40,983$47.00$1,926,201.00View SEC Filing  
8/22/2013Davide MolhoVPSell6,500$47.93$311,545.00View SEC Filing  
8/20/2013Stephen ChubbDirectorSell4,000$47.46$189,840.00View SEC Filing  
8/5/2013Jorg GellerVPSell3,025$46.38$140,299.50View SEC Filing  
8/5/2013Richard WallmanDirectorSell1,500$45.95$68,925.00View SEC Filing  
8/2/2013Davide MolhoVPSell4,100$45.89$188,149.00View SEC Filing  
8/2/2013Deborah Turner KochevarDirectorSell4,447$46.02$204,650.94View SEC Filing  
8/2/2013Thomas AckermanCFOSell26,250$46.03$1,208,287.50View SEC Filing  
6/3/2013Thomas F AckermanCFOSell4,000$42.40$169,600.00View SEC Filing  
5/14/2013James C FosterCEOSell113,810$45.00$5,121,450.00View SEC Filing  
5/10/2013George MassaroDirectorSell2,020$44.09$89,061.80View SEC Filing  
3/13/2013David P JohstVPSell17,038$45.00$766,710.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Charles River Laboratories International (NYSE:CRL)
Latest Headlines for Charles River Laboratories International (NYSE:CRL)
Loading headlines, please wait.



Charles River Laboratories International (CRL) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.